Rhumbline Advisers Raises Stake in Avanos Medical, Inc. $AVNS

Rhumbline Advisers grew its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 36.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 187,251 shares of the company’s stock after acquiring an additional 49,714 shares during the quarter. Rhumbline Advisers owned 0.40% of Avanos Medical worth $2,165,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in shares of Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Avanos Medical by 49.7% during the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after buying an additional 894 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Avanos Medical by 433.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after buying an additional 5,083 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Avanos Medical in the 2nd quarter valued at about $126,000. Finally, Inscription Capital LLC purchased a new stake in Avanos Medical during the 3rd quarter valued at about $135,000. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AVNS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th. Finally, Wall Street Zen lowered shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

Avanos Medical Stock Performance

Shares of AVNS stock opened at $14.12 on Friday. The stock has a fifty day moving average of $13.05 and a 200 day moving average of $12.10. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $15.68. The firm has a market capitalization of $656.44 million, a price-to-earnings ratio of -8.93 and a beta of 1.09. The company has a quick ratio of 1.36, a current ratio of 2.15 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.70 million. During the same period in the previous year, the firm earned $0.43 EPS. The company’s quarterly revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, research analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.